doi: 10.1016/0065-2571(91)90009-b.
Studies on the mechanisms of inhibition of L1210 cell growth by 3,4-dihydroxybenzohydroxamic acid and 3,4-dihydroxybenzamidoxime
Affiliations
- PMID: 1877400
- DOI: 10.1016/0065-2571(91)90009-b
Item in Clipboard
Studies on the mechanisms of inhibition of L1210 cell growth by 3,4-dihydroxybenzohydroxamic acid and 3,4-dihydroxybenzamidoxime
Adv Enzyme Regul.
1991.
Abstract
Didox and Amidox inhibit L1210 cell growth in culture. At least one of the mechanisms in the mode(s) of action of the compounds is directed at the ribonucleotide reductase site. Partially purified preparations of ribonucleotide reductase activity are inhibited by Amidox and Didox. The formation of deoxycytidine nucleotides from [14C]cytidine in intact L1210 cells is also blocked. Didox and Amidox cause the decrease in the intracellular pools of the four dNTPs. Hydroxyurea-resistant L1210 cells are not cross-resistant to either Didox or Amidox. These data suggest that Didox and Amidox are not inhibiting ribonucleotide reductase through a mechanism similar to hydroxyurea.
Similar articles
-
Iron binding capacity of didox (3,4-dihydroxybenzohydroxamic acid) and amidox (3,4-dihydroxybenzamidoxime) new inhibitors of the enzyme ribonucleotide reductase.Life Sci. 1997;61(22):2231-7. doi: 10.1016/s0024-3205(97)00925-9. Life Sci. 1997. PMID: 9393942
-
Iron binding capacity of didox (3,4 dihydroxybenzohydroxamic acid) and amidox (3,4 dihydroxybenzamidoxime) two inhibitors of the enzyme ribonucleotide reductase.Adv Exp Med Biol. 1998;431:599-604. doi: 10.1007/978-1-4615-5381-6_116. Adv Exp Med Biol. 1998. PMID: 9598136
-
Activation of caspases and induction of apoptosis by novel ribonucleotide reductase inhibitors amidox and didox.Exp Hematol. 2001 May;29(5):623-32. doi: 10.1016/s0301-472x(01)00624-5. Exp Hematol. 2001. PMID: 11376876
-
Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone; 3-AP): an inhibitor of ribonucleotide reductase with antineoplastic activity.Adv Enzyme Regul. 1999;39:3-12. doi: 10.1016/s0065-2571(98)00017-x. Adv Enzyme Regul. 1999. PMID: 10470363 Review.
-
Inhibition of nucleoside diphosphate reductase by hydroxybenzohydroxamic acid derivatives.Pharmacol Ther. 1985;29(2):239-54. doi: 10.1016/0163-7258(85)90031-2. Pharmacol Ther. 1985. PMID: 3939037 Review. No abstract available.
Cited by
-
Biochemical and antitumor activity of trimidox, a new inhibitor of ribonucleotide reductase.Cancer Chemother Pharmacol. 1994;34(1):63-6. doi: 10.1007/BF00686113. Cancer Chemother Pharmacol. 1994. PMID: 8174204
-
The Epstein-Barr virus (EBV) deubiquitinating enzyme BPLF1 reduces EBV ribonucleotide reductase activity.J Virol. 2009 May;83(9):4345-53. doi: 10.1128/JVI.02195-08. Epub 2009 Feb 25. J Virol. 2009. PMID: 19244336 Free PMC article.
-
Inhibitors of the Cancer Target Ribonucleotide Reductase, Past and Present.Biomolecules. 2022 Jun 10;12(6):815. doi: 10.3390/biom12060815. Biomolecules. 2022. PMID: 35740940 Free PMC article. Review.
-
Synthesis and testing of new antileukemic Schiff bases of N-hydroxy-N'-aminoguanidine against CCRF-CEM/0 human leukemia cells in vitro and synergism studies with cytarabine (Ara-C).Pharm Res. 1993 Apr;10(4):515-20. doi: 10.1023/a:1018985616389. Pharm Res. 1993. PMID: 8483833